Français
History
- 1953: creation of Biocodex to produce and distribute the yeast "Saccharomyces boulardii" (ULTRA-LEVURE®) in France.
- 1960: first exports.
- 1961: development of a new production method, namely the lyophilization and encapsulation of "Saccharomyces boulardii" (ULTRA-LEVURE®).
- 1966: construction of a plant at Beauvais, specializing exclusively in biosynthesis of the yeast "Saccharomyces boulardii", bringing together all stages of production and packaging, in order to maintain the highest standards of pharmaceutical quality and safety.
- 1968: development and launch of OTIPAX®, analgesic and anti-inflammatory ear solution.
- 1974: new head office at Montrouge and creation of International Department to cope with the strong growth in exports and the domestic market.
- 1978: launch of STIMOL®, antiasthenic.
- 1982: Biocodex' dynamism in exports is rewarded in Lisbon with the International Export Trophy.
- 1987: founding of Biocodex Inc. in Seattle, USA.
- 1989: creation of a department of hospital visits.
- 1990: new Research Center at Compiègne.
- 1994: diversification of Biocodex into the central nervous system sector with the acquisition of the anxiolytic STRESAM®.
- 1995: expansion of product range into the field of pain treatment with the acquisition of the injectable analgesic ACUPAN®.
- 2000: launch of the analgesic BIODALGIC Gé®.
- 2002: european orphan drug status granted for the antiepileptic DIACOMIT®.
- 2003: acquisition of the antidepressant MOCLAMINE®.
- 2005: acquisition of LOGIFLOX® and DECALOGIFLOX®, urinary antibiotics.
- 2006: creation of Offidis, a subsidiary intended for the market of dispensaries
- 2007: european agreement granted for the antiepileptic DIACOMIT®
| Last Updated : January 6, 2009 | © 2009 Biocodex - All Rights Reserved | Terms of Use |